Venlo, the Netherlands, July 18, 2023 (GLOBE NEWSWIRE) -- QIAGEN (QGEN) (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the expansion of its digital PCR (dPCR) offering for the development ...
Firm will seek approval of a range of diagnostic assays for the platform. Qiagen confirmed the receipt or FDA 510(k) clearance for both its Rotor-Gene Q MDx real-time PCR platform, and also the artus ...
QIAGEN N.V. QGEN recently announced the launch of three new kits for use on its QIAcuity systems and a major new software update. These are designed to expand the portfolio of applications for the use ...
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening ...
HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today a series of enhancements for its QIAcuity series of digital PCR (dPCR) ...
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) system ...
QIAGEN’s therascreen PDGFRA RGQ PCR kit approved in U.S. to aid in identifying patients with unresectable or metastatic gastrointestinal stromal tumors positive for the PDGFRA D842V mutation who may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results